Research Link- Relationship Between Disease-Modifying Therapy and Depression in MS

Relationship Between Disease-Modifying Therapy and Depression in MS

“Many prescribers of disease-modifying therapies for multiple sclerosis believe that interferon beta (IFNB) is more likely that glatiramer acetate (GA) to increase depression during the course of MS treatment.  Therefore, newly diagnosed patients with a history of depression are often placed on GA therapy from the onset of MS treatment.  The aim of this study was to examine the relationship between disease-modifying therapy type and depression among patients with relapsing-remitting MS. Patients with RRMS who remained on a single course of therapy (either IFNB or GA) were asked to complete the Beck Depression Inventory at treatment initiation and every 6 months thereafter for up to 4 years. Neither interferon beta nor glatiramer acetate appeared to exacerbate depressive symptoms in patients with relapsing-remitting MS who remain on their initial therapy”

For the original study by Kirzinger et al : click here

beck-depression-inventory-815

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s